69O.F AELIS FARMA SAS EO -004

Healthcare Biotechnology Frankfurt Exchange
0.8300 EUR
Close of Nov 11, 2026
0.6210 2.17
Market cap
EUR 11.3M
P/E
-
P/B
5.36x
ROE
-144.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 69O.F undervalued?

Graham number

The Graham number of AELIS FARMA SAS EO -004 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AELIS FARMA SAS EO -004 fundamental analysis

No fundamental analysis for AELIS FARMA SAS EO -004 yet.

AELIS FARMA SAS EO -004 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AELIS FARMA SAS EO -004

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observ…

Full company profile